Geode Capital Management LLC Has $8.96 Million Position in Personalis, Inc. $PSNL

Geode Capital Management LLC raised its position in Personalis, Inc. (NASDAQ:PSNL) by 165.6% in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,365,598 shares of the company’s stock after purchasing an additional 851,422 shares during the period. Geode Capital Management LLC’s holdings in Personalis were worth $8,960,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently made changes to their positions in PSNL. XTX Topco Ltd increased its position in shares of Personalis by 147.0% in the 1st quarter. XTX Topco Ltd now owns 82,666 shares of the company’s stock valued at $290,000 after buying an additional 49,197 shares in the last quarter. Aberdeen Group plc grew its stake in Personalis by 472.3% in the first quarter. Aberdeen Group plc now owns 1,704,784 shares of the company’s stock valued at $5,984,000 after acquiring an additional 1,406,895 shares during the period. American Century Companies Inc. grew its stake in Personalis by 33.9% in the first quarter. American Century Companies Inc. now owns 67,377 shares of the company’s stock valued at $236,000 after acquiring an additional 17,056 shares during the period. EntryPoint Capital LLC increased its holdings in shares of Personalis by 76.0% in the first quarter. EntryPoint Capital LLC now owns 83,628 shares of the company’s stock worth $294,000 after acquiring an additional 36,115 shares in the last quarter. Finally, Trexquant Investment LP raised its position in shares of Personalis by 455.0% during the first quarter. Trexquant Investment LP now owns 122,959 shares of the company’s stock worth $432,000 after purchasing an additional 100,804 shares during the period. 61.91% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on PSNL shares. Wall Street Zen upgraded Personalis from a “sell” rating to a “hold” rating in a report on Saturday, September 20th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Personalis in a research note on Wednesday, October 8th. BTIG Research increased their price objective on shares of Personalis from $11.00 to $12.00 and gave the stock a “buy” rating in a research report on Tuesday, November 11th. Lake Street Capital restated a “buy” rating and set a $11.00 price objective on shares of Personalis in a report on Wednesday, November 5th. Finally, Needham & Company LLC boosted their price objective on shares of Personalis from $7.00 to $10.00 and gave the company a “buy” rating in a research report on Wednesday, November 5th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $10.57.

Insider Transactions at Personalis

In related news, CEO Christopher M. Hall sold 29,612 shares of the company’s stock in a transaction dated Monday, November 3rd. The stock was sold at an average price of $8.99, for a total transaction of $266,211.88. Following the sale, the chief executive officer owned 148,486 shares in the company, valued at approximately $1,334,889.14. This represents a 16.63% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CFO Aaron Tachibana sold 103,668 shares of the stock in a transaction that occurred on Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the transaction, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at $1,772,857.24. This trade represents a 38.66% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 3.80% of the stock is currently owned by insiders.

Personalis Stock Up 3.0%

Shares of PSNL opened at $10.48 on Friday. Personalis, Inc. has a twelve month low of $2.83 and a twelve month high of $11.40. The stock has a market capitalization of $930.62 million, a P/E ratio of -11.91 and a beta of 1.99. The company has a 50 day moving average of $8.70 and a 200-day moving average of $6.70.

Personalis (NASDAQ:PSNL) last announced its earnings results on Tuesday, November 4th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.28) by $0.04. Personalis had a negative net margin of 106.92% and a negative return on equity of 38.25%. The business had revenue of $14.50 million during the quarter, compared to analysts’ expectations of $13.31 million. On average, sell-side analysts anticipate that Personalis, Inc. will post -1.4 earnings per share for the current fiscal year.

About Personalis

Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.